Adrenal Hyperplasia and Adenomas Are Associated with Inhibition of Phosphodiesterase 11A in Carriers of PDE11A Sequence Variants That Are Frequent in the Population
Open Access
- 15 December 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (24) , 11571-11575
Abstract
G protein–coupled receptors (GPCR) and the epidermal growth factor receptor (EGFR) are often both overexpressed and contribute to the growth of cancers by activating autocrine pathways. GPCR ligands have been reported to trigger EGFR signaling via receptor cross-talk in cancer cells. Here, we show that GPCR ligands prostaglandin E2 (PGE2) and bradykinin (BK) activate EGFR signaling. Inhibition of EGFR using several strategies, including small-molecule inhibitors and an EGFR-specific antibody, resulted in partial attenuation of signaling downstream of EGFR. PGE2 and BK triggered EGFR signaling by increasing selective autocrine release of transforming growth factor-α (TGF-α). Inhibition of tumor necrosis factor-α–converting enzyme abrogated BK- or PGE2-mediated activation of EGFR signaling. Both PGE2 and BK stimulated head and neck squamous cell carcinoma (HNSCC) invasion via EGFR. Treatment of HNSCC cells with the BK antagonist CU201 resulted in growth inhibition. The combination of CU201 with the EGFR small-molecule inhibitor erlotinib resulted in additive inhibitory effects on HNSCC cell growth in vitro. Inhibition of the PGE2 synthesis pathway with sulindac induced HNSCC cytotoxicity at high doses (EC50, 620 μmol/L). However, combined inhibition of both EGFR with the tyrosine kinase inhibitor erlotinib and GPCR with sulindac at low doses of 6 and 310 μmol/L, respectively, resulted in synergistic killing of HNSCC tumor cells. Combined blockade of both EGFR and GPCRs may be a rational strategy to treat cancers, including HNSCC that shows cross-talk between GPCR and EGFR signaling pathways. (Cancer Res 2006; 66(24): 11831-9)Keywords
All Related Versions
This publication has 15 references indexed in Scilit:
- A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasiaNature Genetics, 2006
- Analysis and visualization of chromosomal abnormalities in SNP data with SNPscanBMC Bioinformatics, 2006
- Expression of PDE11A in Normal and Malignant Human TissuesJournal of Histochemistry & Cytochemistry, 2005
- 3′,5′-Cyclic nucleotide phosphodiesterase 11A: localization in human tissuesInternational Journal Of Impotence Research, 2005
- Cyclical Cushing Syndrome Presenting in Infancy: An Early Form of Primary Pigmented Nodular Adrenocortical Disease, or a New Entity?The Journal of Clinical Endocrinology & Metabolism, 2004
- The New York Cancer Project: Rationale, Organization, Design, and Baseline CharacteristicsJournal of Urban Health, 2004
- Mutations of thePRKAR1AGene in Cushing’s Syndrome due to Sporadic Primary Pigmented Nodular Adrenocortical DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2002
- Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient EvaluationThe Journal of Clinical Endocrinology & Metabolism, 2001
- Genomic organization of the human phosphodiesterase PDE11A geneEuropean Journal of Biochemistry, 2001
- Clinical and Genetic Analysis of Primary Bilateral Adrenal Diseases (Micro- and Macronodular Disease) Leading to Cushing SyndromeHormone and Metabolic Research, 1998